A Lyme disease vaccine produced by Pfizer and Valneva was deemed 70 percent effective by the companies after they reviewed ...

Scientists found that the experimental vaccine was more than 70% effective at preventing Lyme disease in a trial of nearly 10,000 volunteers.

Pfizer logo (Photo Illustration by Nikolas Kokovlis/NurPhoto via Getty Images) (NEW YORK) — Earlier this week, pharmaceutical ...

Pfizer (NYSE:PFE) has quietly built momentum in 2026, with shares up 6.61% year-to-date and 2.70% over the past year. The stock is currently trading near $26.84 but remains well below its 52-week high ...

Earlier this week, pharmaceutical company Pfizer and its partner Valneva announced that an experimental Lyme disease vaccine ...

The fresh funding will help the biotech startup advance a candidate to treat a genetic disorder, “ATTR-CM,” that has become a battleground for companies like Pfizer, Alnylam and BridgeBio.

Pfizer said its experimental Lyme disease vaccine was more than 70% efficacious in reducing confirmed cases of the tickborne ...

Protalix BioTherapeutics, Inc. is rated a Buy due to robust FY26 revenue guidance of $78–83 million. Learn more about PLX stock here.

New capability reinforces dominKnow’s intentional AI strategy—focused on control, quality, and enterprise-scale impact ...

As another tick season settles in across Greater Boston, Pfizer is betting that its experimental Lyme disease vaccine could eventually change the game. The shot is still in testing and years away from ...

Pfizer and Valneva's Lyme disease vaccine candidate demonstrated more than 70% efficacy in a phase III trial, but pre-determined statistical criterion for the primary endpoint was not met, the ...

"The window to shape the oral GLP-1 market is open now...."Early-stage discussions with several multinational pharmaceutical companies currently underway ...